Aldn-084 (2024)

The Astraeus floated in a quiet, sun‑bleached sector of the Perseus Arm, its hull a muted silver against the endless black. Its mission was simple, if not modest: to chart the uninhabited worlds of the outer rim and collect data on anomalous radiation pockets that the Galactic Survey had flagged as “potentially interesting.” The ship’s name—Astraeus, after the Greek god of dusk—seemed fitting for a vessel that spent most of its days chasing the faint glow of distant suns.

On the third day of their drift around the carbon‑rich planet Xalor IV, the ship's long‑range scanner caught a flicker—a narrowband transmission that defied all known astrophysical signatures. It repeated with a cadence of 4.2 seconds, a simple pulse that rose and fell like a heartbeat. The crew logged it as ALDN‑084.

“ALDN—what’s that?” asked Dr. Mei Lian, the ship’s chief xenobiologist, peering over a holo‑screen. Her amber eyes flickered with the same excitement that had driven her to leave the orbital labs of Luna. ALDN-084

“It’s a designation we use for unidentified low‑density noise,” replied Commander Rafiq al‑Saadi, the captain. “But this—this is a pattern. It’s not random.”

The ship’s communications officer, a lanky tech named Jiro, pulled up a spectral analysis. The signal sat in the 7.3 GHz band, a frequency used by deep‑space beacons, but the modulation was unlike anything in the Federation’s database. The Astraeus floated in a quiet, sun‑bleached sector

“It looks… intentional,” Jiro whispered, as if speaking too loudly might shatter the fragile mystery.

| Property | Reported Value / Comment | |----------|--------------------------| | IUPAC name | Not disclosed (proprietary) | | Molecular formula | C₂₁H₂₅N₅O₂ (estimated from patent) | | Molecular weight | ≈ 383 Da | | Core scaffold | 1,3,5‑triazine linked to a heterocyclic quinazolinone via a sulfonamide bridge | | LogP (XLogP3-AA) | 2.8 – 3.2 (moderately lipophilic) | | pKa | 6.4 (basic amine), 9.8 (sulfonamide NH) | | Solubility | ~10 µM in PBS (pH 7.4); > 100 µM in 10 % DMSO/PBS | | Stability | Chemically stable at 25 °C for ≥ 12 months (solid form) | | Formulation | Currently supplied as a free‑base powder; developing an oral tablet (≤ 200 mg) and an IV solution (5 mg · mL⁻¹) | | Cellular read‑out | Effect of ALDN‑084 (in

The above values are derived from the patent’s “Example 7” and Aladdin’s internal data sheet (2024).

| Cellular read‑out | Effect of ALDN‑084 (in vitro) | |-------------------|------------------------------| | LPS‑stimulated macrophages (TNF‑α, IL‑1β) | ↓ > 80 % (IC₅₀ ≈ 10 nM) | | IFN‑γ‑primed astrocytes (CXCL10) | ↓ ≈ 70 % (IC₅₀ ≈ 25 nM) | | Oxidative stress (H₂O₂‑challenge) (ROS) | ↓ ≈ 55 % (EC₅₀ ≈ 80 nM) | | Phagocytic clearance of Aβ | ↑ ≈ 30 % (dose‑dependent, 100 nM) |